Literature DB >> 27228966

The association of change in medication regimen and use of inappropriate medication based on beers criteria with adverse outcomes in Japanese long-term care facilities.

Shinya Ishii1, Taro Kojima1, Kazuhiko Ezawa2,3, Kentaro Higashi4, Yukihiko Ikebata5, Yozo Takehisa6, Masahiro Akishita1.   

Abstract

AIM: To describe medication use including potentially inappropriate medication (PIM) and examine the association between adverse outcomes and patient factors including PIM use in Japanese elderly patients in long-term care facilities.
METHODS: This was a retrospective cohort study of 470 patients in 53 Geriatric Health Service Facilities and 44 Sanatorium Type Medical Care Facilities for the Elderly Requiring Long Term Care. Standardized forms were used to collect information including oral and parenteral medication use on admission, and 1 month and 3 months after admission. PIMs were determined by the 2003 or 2012 Beers criteria. Adverse outcomes were any medical events leading to emergency department transfer, hospitalization to acute care hospitals or death.
RESULTS: A total of 2,227 oral medications and 197 parenteral medications were prescribed for 470 patients on admission. PIM exposure based on the 2003 and 2012 Beers criteria was observed in 11.9% and 37.5%, respectively. Adverse outcomes within 3 months after admission were observed in 8.9% of the entire cohort, and were associated with age, sex, facility type and number of parenteral medications on admission. Adverse outcomes between one and three months after admission were associated with age, sex, number of parenteral medications at one month, and a change in the number of oral and parenteral medications within one month after admission. PIM exposure was not associated with adverse outcomes in any models.
CONCLUSIONS: Use of PIM was prevalent in long-term care facilities. Our findings support the importance of comprehensive assessment of medication regimens including parenteral medication. Geriatr Gerontol Int 2017; 17: 591-597.
© 2016 Japan Geriatrics Society.

Entities:  

Keywords:  adverse drug events; long term care facilities; potentially inappropriate medications

Mesh:

Year:  2016        PMID: 27228966     DOI: 10.1111/ggi.12761

Source DB:  PubMed          Journal:  Geriatr Gerontol Int        ISSN: 1447-0594            Impact factor:   2.730


  6 in total

1.  Over-the-counter medications containing diphenhydramine and doxylamine used by older adults to improve sleep.

Authors:  Olufunmilola Abraham; Loren Schleiden; Steven M Albert
Journal:  Int J Clin Pharm       Date:  2017-05-02

2.  Potentially inappropriate medication use in nursing homes: an observational study using the NORGEP-NH criteria.

Authors:  Gunhild Nyborg; Mette Brekke; Jørund Straand; Svein Gjelstad; Maria Romøren
Journal:  BMC Geriatr       Date:  2017-09-19       Impact factor: 3.921

3.  Regular medications prescribed to elderly neurosurgical inpatients and the impact of hospitalization on potentially inappropriate medications.

Authors:  Narushi Sugii; Hiroyuki Fujimori; Naoaki Sato; Akira Matsumura
Journal:  J Rural Med       Date:  2018-11-29

4.  American Geriatrics Society-Beers Criteria and adverse drug reactions: a comparative cross-sectional study of Nigerian and South African older inpatients.

Authors:  Sule Ajibola Saka; Manimbulu Nlooto; Frasia Oosthuizen
Journal:  Clin Interv Aging       Date:  2018-11-19       Impact factor: 4.458

5.  Evaluation of changes in prescription among Japanese elderly patients before and after transition to home care.

Authors:  Shoichi Masumoto; Mikiya Sato; Tomotsugu Yamakawa; Shuhei Hamada; Takashi Inaba; Yoshihiro Kataoka; Sachiko Ozone; Shoji Yokoya; Jun Hamano
Journal:  J Gen Fam Med       Date:  2021-11-08

6.  Identifying drug substances of screening tool for older persons' appropriate prescriptions for Japanese.

Authors:  Kaori Nomura; Taro Kojima; Shinya Ishii; Takuto Yonekawa; Masahiro Akishita; Manabu Akazawa
Journal:  BMC Geriatr       Date:  2018-07-03       Impact factor: 3.921

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.